Uveitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Uveitis - Pipeline Review, H1 2016', provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews pipeline therapeutics for Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Uveitis therapeutics and enlists all their major and minor projects - The report assesses Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Uveitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Uveitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Uveitis Overview 8 Therapeutics Development 9 Pipeline Products for Uveitis - Overview 9 Pipeline Products for Uveitis - Comparative Analysis 10 Uveitis - Therapeutics under Development by Companies 11 Uveitis - Therapeutics under Investigation by Universities/Institutes 14 Uveitis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Uveitis - Products under Development by Companies 18 Uveitis - Products under Investigation by Universities/Institutes 22 Uveitis - Companies Involved in Therapeutics Development 23 2-BBB Medicines BV 23 AbbVie Inc. 24 Aciont Inc. 25 Aldeyra Therapeutics, Inc. 26 Apitope International NV 27 Astellas Pharma Inc. 28 Bausch & Lomb Incorporated 29 Bionomics Limited 30 Bristol-Myers Squibb Company 31 Can-Fite BioPharma Ltd. 32 Clearside BioMedical, Inc. 33 Effimune SAS 34 Endocyte, Inc. 35 Enzo Biochem, Inc. 36 EyeGate Pharmaceuticals, Inc. 37 HanAll Biopharma Co., Ltd. 38 Icon Bioscience, Inc. 39 Johnson & Johnson 40 Kineta, Inc. 41 Mitotech S.A. 42 Neuroptis Biotech 43 Novartis AG 44 Oculis ehf 45 OncoNOx ApS 46 Palatin Technologies, Inc. 47 Panoptes Pharma Ges.m.b.H. 48 Pfizer Inc. 49 Precision Ocular Ltd 50 pSivida Corp. 51 Regeneron Pharmaceuticals, Inc. 52 Santen Pharmaceutical Co., Ltd. 53 SynDevRx, Inc. 54 ThromboGenics NV 55 TxCell SA 56 Virogenomics BioDevelopment, Inc. 57 Uveitis - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Target 59 Assessment by Mechanism of Action 62 Assessment by Route of Administration 64 Assessment by Molecule Type 66 Drug Profiles 68 2-B3201 - Drug Profile 68 abatacept - Drug Profile 70 adalimumab - Drug Profile 73 ANV-103 - Drug Profile 76 ATXUV-1 - Drug Profile 77 ATXUV-2 - Drug Profile 78 B27-PD - Drug Profile 79 BNC-164 - Drug Profile 81 celecoxib - Drug Profile 82 Col-Treg - Drug Profile 84 CVX-001 - Drug Profile 86 cyclosporine SR - Drug Profile 87 Cytectin - Drug Profile 88 dalazatide - Drug Profile 89 dexamethasone acetate - Drug Profile 91 dexamethasone acetate - Drug Profile 93 dexamethasone acetate - Drug Profile 95 dexamethasone acetate - Drug Profile 96 dexamethasone sodium phosphate - Drug Profile 97 Drug for Chronic Uveitis - Drug Profile 99 Drugs for Retinal Diseases - Drug Profile 100 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 101 EC-1669 - Drug Profile 102 fluocinolone acetonide - Drug Profile 103 fluocinolone acetonide SR - Drug Profile 104 FR-104 - Drug Profile 106 HL-036 - Drug Profile 108 INV-17 - Drug Profile 109 IVMED-20 - Drug Profile 110 KPI-190 - Drug Profile 111 LME-636 - Drug Profile 112 lodamin - Drug Profile 113 methotrexate - Drug Profile 114 NOP-3 - Drug Profile 115 NS-2 - Drug Profile 116 OX-1001 - Drug Profile 118 PA-2612 - Drug Profile 119 piclidenoson - Drug Profile 120 PL-8177 - Drug Profile 122 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 123 PP-001 - Drug Profile 125 PPL-003 - Drug Profile 126 Recombinant Enzymes for Uveitis - Drug Profile 128 Recombinant Peptides to Modulate TCR for Uveitis - Drug Profile 129 sarilumab - Drug Profile 130 sirolimus - Drug Profile 133 Small Molecules to Inhibit 5-lipoxygenase for Uveitis - Drug Profile 135 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 136 tesidolumab - Drug Profile 137 TG-931 - Drug Profile 139 TOP-1288 - Drug Profile 140 triamcinolone acetonide - Drug Profile 141 triamcinolone acetonide - Drug Profile 142 Uveitis - Recent Pipeline Updates 144 Uveitis - Dormant Projects 186 Uveitis - Discontinued Products 189 Uveitis - Product Development Milestones 190 Featured News & Press Releases 190 Appendix 198 Methodology 198 Coverage 198 Secondary Research 198 Primary Research 198 Expert Panel Validation 198 Contact Us 198 Disclaimer 199
List of Tables
Number of Products under Development for Uveitis, H1 2016 13 Number of Products under Development for Uveitis - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Development by Companies, H1 2016 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Comparative Analysis by Late Stage Development, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Development by Companies, H1 2016 (Contd..3) 25 Products under Investigation by Universities/Institutes, H1 2016 26 Uveitis - Pipeline by 2-BBB Medicines BV, H1 2016 27 Uveitis - Pipeline by AbbVie Inc., H1 2016 28 Uveitis - Pipeline by Aciont Inc., H1 2016 29 Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 30 Uveitis - Pipeline by Apitope International NV, H1 2016 31 Uveitis - Pipeline by Astellas Pharma Inc., H1 2016 32 Uveitis - Pipeline by Bausch & Lomb Incorporated, H1 2016 33 Uveitis - Pipeline by Bionomics Limited, H1 2016 34 Uveitis - Pipeline by Bristol-Myers Squibb Company, H1 2016 35 Uveitis - Pipeline by Can-Fite BioPharma Ltd., H1 2016 36 Uveitis - Pipeline by Clearside BioMedical, Inc., H1 2016 37 Uveitis - Pipeline by Effimune SAS, H1 2016 38 Uveitis - Pipeline by Endocyte, Inc., H1 2016 39 Uveitis - Pipeline by Enzo Biochem, Inc., H1 2016 40 Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 41 Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 42 Uveitis - Pipeline by Icon Bioscience, Inc., H1 2016 43 Uveitis - Pipeline by Johnson & Johnson, H1 2016 44 Uveitis - Pipeline by Kineta, Inc., H1 2016 45 Uveitis - Pipeline by Mitotech S.A., H1 2016 46 Uveitis - Pipeline by Neuroptis Biotech, H1 2016 47 Uveitis - Pipeline by Novartis AG, H1 2016 48 Uveitis - Pipeline by Oculis ehf, H1 2016 49 Uveitis - Pipeline by OncoNOx ApS, H1 2016 50 Uveitis - Pipeline by Palatin Technologies, Inc., H1 2016 51 Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H1 2016 52 Uveitis - Pipeline by Pfizer Inc., H1 2016 53 Uveitis - Pipeline by Precision Ocular Ltd, H1 2016 54 Uveitis - Pipeline by pSivida Corp., H1 2016 55 Uveitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 56 Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 57 Uveitis - Pipeline by SynDevRx, Inc., H1 2016 58 Uveitis - Pipeline by ThromboGenics NV, H1 2016 59 Uveitis - Pipeline by TxCell SA, H1 2016 60 Uveitis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 61 Assessment by Monotherapy Products, H1 2016 62 Number of Products by Stage and Target, H1 2016 64 Number of Products by Stage and Mechanism of Action, H1 2016 67 Number of Products by Stage and Route of Administration, H1 2016 69 Number of Products by Stage and Molecule Type, H1 2016 71 Uveitis Therapeutics - Recent Pipeline Updates, H1 2016 148 Uveitis - Dormant Projects, H1 2016 190 Uveitis - Dormant Projects (Contd..1), H1 2016 191 Uveitis - Dormant Projects (Contd..2), H1 2016 192 Uveitis - Discontinued Products, H1 2016 193
List of Figures
Number of Products under Development for Uveitis, H1 2016 13 Number of Products under Development for Uveitis - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Comparative Analysis by Late Stage Development, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Products, H1 2016 21 Assessment by Monotherapy Products, H1 2016 62 Number of Products by Top 10 Targets, H1 2016 63 Number of Products by Stage and Top 10 Targets, H1 2016 63 Number of Products by Top 10 Mechanism of Actions, H1 2016 66 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 66 Number of Products by Top 10 Routes of Administration, H1 2016 68 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 68 Number of Products by Top 10 Molecule Types, H1 2016 70 Number of Products by Stage and Top 10 Molecule Types, H1 2016 70
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.